Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol-Reference-Cited by-同舟云学术

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

Published:2010-07-29 Issue:9 Volume:24 Page:1599-1606
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

van der Velden V H J,van der Sluijs-Geling A,Gibson B E S,te Marvelde J G,Hoogeveen P G,Hop W C J,Wheatley K,Bierings M B,Schuurhuis G J,de Graaf S S N,van Wering E R,van Dongen J J M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2010153.pdf

Reference30 articles.

1. Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003; 123: 243–252.

2. Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol 2006; 24: 3686–3692.

3. Sievers EL, Lange BJ, Buckley JD, Smith FO, Wells DA, Daigneault-Creech CA et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst 1996; 88: 1483–1488.

4. Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group Study of 252 patients with acute myeloid leukemia. Blood 2003; 101: 3398–3406.

5. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T . Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078–3085.

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia;Blood Advances;2024-06-14

2. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients;European Journal of Haematology;2024-02-11

3. Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia;BMC Cancer;2024-01-09

4. Measurable Residual Disease Assessment in Pediatric AML;Pediatric Oncology;2024

5. A 19‐color single‐tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia;Cytometry Part A;2023-12-08